Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Aulitzky

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Journal of Cancer Research and Clinical Oncology|January 1, 1988
Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trialF Porzsolt, D Messerer, R Hautmann, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1986
Treatment of hairy-cell leukemia with recombinant alpha 2-interferonZ N Berneman, G Gastl, D Gangji, et al.
Journal of Interferon Research|August 1, 1989
Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancerW E Aulitzky, W Aulitzky, G Gastl, et al.
Leukemia|June 1, 1989
Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patientsG Gastl, M Werter, B De Pauw, et al.
British Journal of Haematology|October 16, 1999
Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemiaM Lindauer, D Domkin, H Döhner, et al.
Acta Histochemica|August 12, 1999
Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: is there any prognostic relevance?P Fritz, R Seizer-Schmidt, T E Mürdter, et al.
Cytometry. Part B, Clinical Cytometry|April 30, 2003
Immunophenotyping is an independent factor for risk stratification in AMLR Repp, U Schaekel, G Helm, et al.
Annals of Hematology|June 1, 1996
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study GroupJ Thaler, G Gastl, T Fluckinger, et al.
Immunobiology|January 1, 1996
CD4 monoclonal antibody VIT4 in human alloimmune response in vitro and in vivoD Nachbaur, D Niederwieser, G Aichinger, et al.
Bone Marrow Transplantation|June 19, 1998
Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CMLT Fischer, A Neubauer, J Mohm, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Journal of Cancer Research and Clinical Oncology|January 1, 1988
Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trialF Porzsolt, D Messerer, R Hautmann, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1986
Treatment of hairy-cell leukemia with recombinant alpha 2-interferonZ N Berneman, G Gastl, D Gangji, et al.
Journal of Interferon Research|August 1, 1989
Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancerW E Aulitzky, W Aulitzky, G Gastl, et al.
Leukemia|June 1, 1989
Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patientsG Gastl, M Werter, B De Pauw, et al.
British Journal of Haematology|October 16, 1999
Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemiaM Lindauer, D Domkin, H Döhner, et al.
Acta Histochemica|August 12, 1999
Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: is there any prognostic relevance?P Fritz, R Seizer-Schmidt, T E Mürdter, et al.
Cytometry. Part B, Clinical Cytometry|April 30, 2003
Immunophenotyping is an independent factor for risk stratification in AMLR Repp, U Schaekel, G Helm, et al.
Annals of Hematology|June 1, 1996
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study GroupJ Thaler, G Gastl, T Fluckinger, et al.
Immunobiology|January 1, 1996
CD4 monoclonal antibody VIT4 in human alloimmune response in vitro and in vivoD Nachbaur, D Niederwieser, G Aichinger, et al.
Bone Marrow Transplantation|June 19, 1998
Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CMLT Fischer, A Neubauer, J Mohm, et al.
Pageof 7